FDA Puts Out Alert on Halted Merck & Co. Trials for Keytruda
FDA has put out an alert regarding the risks associated with using Keytruda in combination with other anti-cancer drugs based on interim results from two clinical trials that showed increased risk of death.
On Aug. 31, 2017, FDA issued a statement to inform the public, health care professionals, and oncology clinical investigators about the risks associated with using Keytruda (pembrolizumab), Merck & Co.’s anti-cancer biologic, in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for treating multiple myeloma. Keytruda is currently not approved for treating multiple myeloma, according to FDA in a press release.
The agency issued the statement based on data from two recently halted clinical trials. FDA required the discontinuation of the two trials on July 3, 2017 because interim results from both trials demonstrated an increased risk of death for patients receiving Keytruda in combination with an immunomodulatory agent, as compared to the control group. Keytruda, initially approved by FDA in September 2014 for treating unresectable or metastatic melanoma, is a blockbuster product for Merck with 2016 sales of $1.4 billion.
Merck, which had been notified of the issue through an external data monitoring committee, had earlier suspended the trials to enrollment on June 12, 2017. Other studies of Keytruda, however, continue unchanged, Merck said in a company press release.
FDA’s statement does not apply to patients taking Keytruda for an approved indication. Keytruda’s currently approved indications include treatment of melanoma, lung cancer, head and neck cancer, classical Hodgkin lymphoma, urothelial carcinoma, and microsatellite instability-high cancer.
Other multiple myeloma clinical trials of Keytruda, other programmed death (PD)-1/PD-L1 cancer drugs and other combinations are currently undergoing clinical evaluation. FDA will be working directly with sponsors of Keytruda and other PD-1/PD-L1 cancer drugs and clinical investigators conducting clinical trials in patients with multiple myeloma to determine the extent of the safety issue.
Source: FDA and Merck & Co.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
